CNS gene delivery using peripheral administration of AAV vectors
US12351816B2 · kind B2 · utility
0Cited by
1References
8Claims
0Family size
Assignees
Inventor
Key dates
| Filing date | Aug 1, 2023 |
| Grant date | Jul 8, 2025 |
| Priority date | — |
| Expiry date | Aug 1, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2750/14143
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compositions and methods for the delivery of therapeutic proteins to the CNS using recombinant AAV vectors. More specifically, the invention relates to compositions and methods for delivering proteins into the cerebrospinal fluid of mammalian subjects through peripheral administration of AAV vectors. The invention may be used to treat various disorders of the central nervous system, including degenerative diseases and motor neuron diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.